In-office serial intralesional steroid injection for subglottic stenosis: Case series of 14 patients with multiple etiologies
Name:
In_office_serial_intralesional.pdf
Size:
236.8Kb
Format:
PDF
Description:
Final Published Version
Affiliation
College of Medicine, University of Arizona–PhoenixDepartment of Otolaryngology, College of Medicine, University of Arizona–Tucson
Issue Date
2024-02-08Keywords
in-office treatmentserial intralesional steroid injection
subglottic stenosis
surgery-free interval
Metadata
Show full item recordPublisher
John Wiley and Sons IncCitation
Wehbi N, Gleadhill CME, Ahmadian D, Skirko JR, Yip HT. In-office serial intralesional steroid injection for subglottic stenosis: case series of 14 patients with multiple etiologies. World J Otorhinolaryngol Head Neck Surg. 2024; 1-6. doi:10.1002/wjo2.159Rights
© 2024 The Authors. World Journal of Otorhinolaryngology - Head and Neck Surgery published by John Wiley & Sons Ltd on behalf of Chinese Medical Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Objective: Subglottic stenosis (SGS) is commonly treated with endoscopic dilations or tracheal resection. Since office-based serial intralesional steroid injections (SILSI) were first reported in 2017, they have been established as an effective, less invasive treatment alternative or adjunct. The aim of this study is to add to the literature investigating the efficacy of office-based SILSIs for idiopathic and post-intubation SGS patients, specifically studying surgery-free intervals (SFIs) and discussing our experience with SILSI treatment order and stenosis grade. Methods: This study is a retrospective case series of 14 patients with subglottic stenosis treated with in-office serial intralesional steroid injections as a primary or adjuvant treatment from 2018 to 2022 in an academic tertiary care center. Results: Of seven patients with calculable SFI, a mean SFI increase of 481.28 days was observed following SILSI treatment (p = 0.042). Ten patients in our cohort presented with idiopathic or post-intubation grade 2 SGS and were managed successfully with a combination of endoscopic dilation and SILSI. Two patients with post-intubation grade 1 SGS were managed successfully with SILSI as their primary treatment. Two patients with post-intubation grade 3 SGS required a tracheal resection and did not benefit from SILSI. Conclusions: We have found that SFI significantly increased following SILSI initiation. Although statistical power was limited given the small sample size, our findings suggest that SILSI may be an effective primary treatment in low-grade stenosis. SILSI as an adjuvant to endoscopic dilation may be most effective in intermediate-grade stenosis. SILSI may not be effective in high-grade stenosis patients who failed prior endoscopic treatment. © 2024 The Authors. World Journal of Otorhinolaryngology - Head and Neck Surgery published by John Wiley & Sons Ltd on behalf of Chinese Medical Association.Note
Open access journalISSN
2095-8811DOI
10.1002/wjo2.159Version
Final Published Versionae974a485f413a2113503eed53cd6c53
10.1002/wjo2.159
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2024 The Authors. World Journal of Otorhinolaryngology - Head and Neck Surgery published by John Wiley & Sons Ltd on behalf of Chinese Medical Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License.